<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gu C</submitter><funding>Natural Science Foundation of Shandong Province</funding><pagination>14492-14501</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9102048</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(23)</volume><pubmed_abstract>Two series of new pirfenidone derivatives, in which phenyl groups or benzyl groups are attached to the nitrogen atom of the pyridin-2(1&lt;i>H&lt;/i>)-one moiety were synthesized and evaluated as anti-fibrosis agents. Among them, compound 5d, with a (&lt;i>S&lt;/i>)-2-(dimethylamino) propanamido group in the R&lt;sub>2&lt;/sub> position (series 1) exhibited 10 times the anti-fibrosis activity (IC&lt;sub>50&lt;/sub>: 0.245 mM) of pirfenidone (IC&lt;sub>50&lt;/sub>: 2.75 mM). Compound 9d (series 2) gave an IC&lt;sub>50&lt;/sub> of 0.035 mM against the human fibroblast cell line HFL1. The mechanism of the optimal compound inhibiting fibrosis was also studied.</pubmed_abstract><journal>RSC advances</journal><pubmed_title>Synthesis and evaluation of new pirfenidone derivatives as anti-fibrosis agents.</pubmed_title><pmcid>PMC9102048</pmcid><funding_grant_id>ZR2021QB172</funding_grant_id><pubmed_authors>Li W</pubmed_authors><pubmed_authors>An B</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Gu C</pubmed_authors><pubmed_authors>Yang L</pubmed_authors><pubmed_authors>Hu W</pubmed_authors><pubmed_authors>Yao H</pubmed_authors><pubmed_authors>Ju Q</pubmed_authors></additional><is_claimable>false</is_claimable><name>Synthesis and evaluation of new pirfenidone derivatives as anti-fibrosis agents.</name><description>Two series of new pirfenidone derivatives, in which phenyl groups or benzyl groups are attached to the nitrogen atom of the pyridin-2(1&lt;i>H&lt;/i>)-one moiety were synthesized and evaluated as anti-fibrosis agents. Among them, compound 5d, with a (&lt;i>S&lt;/i>)-2-(dimethylamino) propanamido group in the R&lt;sub>2&lt;/sub> position (series 1) exhibited 10 times the anti-fibrosis activity (IC&lt;sub>50&lt;/sub>: 0.245 mM) of pirfenidone (IC&lt;sub>50&lt;/sub>: 2.75 mM). Compound 9d (series 2) gave an IC&lt;sub>50&lt;/sub> of 0.035 mM against the human fibroblast cell line HFL1. The mechanism of the optimal compound inhibiting fibrosis was also studied.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2026-05-10T01:39:54.513Z</modification><creation>2025-02-19T01:12:36.896Z</creation></dates><accession>S-EPMC9102048</accession><cross_references><pubmed>35702193</pubmed><doi>10.1039/d2ra00990k</doi></cross_references></HashMap>